Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
Oh ST, Verstovsek S, Gupta V, Platzbecker U, Devos T, Kiladjian JJ, McLornan DP, Perkins A, Fox ML, McMullin MF, Mead AJ, Egyed M, Mayer J, Sacha T, Kawashima J, Huang M, Strouse B, Mesa R.
Oh ST, et al. Among authors: perkins a.
EJHaem. 2024 Feb 5;5(1):105-116. doi: 10.1002/jha2.854. eCollection 2024 Feb.
EJHaem. 2024.
PMID: 38406514
Free PMC article.